Fig. 4: Sucralose treatment dampens T cell-mediated inflammation in models of autoimmunity.

a,b, NOD/ShiLtJ type 1 diabetes model in mice given water (n = 8), 0.72 mg ml⁻¹ Scrl (n = 9) or 0.17 mg ml⁻¹ Scrl (n = 9). a, Schematic of the model. b, Disease-free survival. c, Schematic of the T cell-induced colitis model. d–f, CD45.2 Tcra^−/− recipient mice treated with (n = 6) or without (n = 5) 0.72 mg ml⁻¹ Scrl. d, The percentage of congenic CD45.1⁺CD4⁺ donor T cells in the mLN 3 weeks after transplantation. e, Representative flow cytometry plot of lymphocytes from the mLN that were re-stimulated and analysed for the expression of IFNγ and CD4. f, The percentage of CD4⁺CD45.1⁺ donor cells in the mLN that express IFNγ. g,h, Analysis of mLNs from recipient CD45.2 Tcra^−/− mice given water (n = 8) or 0.17 mg ml⁻¹ Scrl (n = 8). g, The total frequency of CD45.1⁺CD4⁺ donor T cells. h, The frequency of CD4⁺ donor T cells expressing Ki67 and IFNγ. Data are mean ± s.e.m. (d,f–h). Each dot (d,f–h) represents a biological replicate; data are representative of two (d–f) or three (g,h) independent experiments. Significance was tested using unpaired two-tailed Student’s t-test (d,f–h) and log rank Mantel–Cox test (b) for either dose of Scrl versus water.

Source data